Lasers in Medical Science· 2026Q2
Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia – a randomized, controlled, clinical study
- 0citations
- Q2SCImago
- 2026year
Short summary
A pilot study found that non-ablative fractional laser (NAFL)-assisted delivery of growth factor serums improved hair density by 25.6% and thickness in patients with androgenetic alopecia (AGA), with similar efficacy but higher satisfaction compared to laser alone.
AI-generated from the title and abstract; the full text is not read.
Key points
- NAFL-assisted growth factor serum delivery improved hair density by 25.6% and thickness in AGA patients.
- Hair density increased by 22.7% with NAFL-serum delivery alone.
- Laser therapy without serum showed minimal hair density improvement (4.9%).
- Triple therapy (NAFL-serum-red light) led to higher patient satisfaction than dual therapy (NAFL-serum).
- No severe adverse events were observed in any treatment group.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Androgenetic alopecia (AGA) is the most common form of hair loss and can significantly impact quality of life. Emerging non-invasive treatments include laser-assisted delivery of biomimetic growth factor–based serums. The aim of the study was to evaluate the safety and efficacy of non-ablative fractional laser (NAFL)–assisted delivery, with or without adjunct red light therapy, in patients with AGA. In this pilot study, patients were randomly assigned to: (I) NAFL-assisted serum delivery plus red light therapy (triple), (II) NAFL-assisted serum delivery alone (dual), or (III) NAFL plus red light therapy without serum (EBD-only). Primary outcomes were hair density and thickness. Secondary outcomes included patient satisfaction, tolerability, and adverse events. Hair density increased in all groups, with greater improvement in the triple (25.6 ± 7.0 %) and dual (22.7 ± 3.4 %) groups compared to EBD-only (4.9 ± 9.2 %). Hair thickness improved in both serum groups but not in the EBD-only group. Clinical outcomes were similar between triple and dual treatments, though satisfaction was higher with triple therapy. No severe adverse events occurred. Preliminary evidence suggests that NAFL-assisted delivery of biomimetic growth factors is a safe and effective non-invasive treatment for AGA.
The authors' abstract, as published at the source. Lasers in Medical Science, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Urology
UrologyMedicine